Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Packaging & closure defects

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination.

318 FDA drug recalls with this cause, newest first.

These recalls involve the container rather than the contents - failed child-resistant closures, leaking bags or vials, cracked cartridges, blister packs with holes, or a delivery device (pump, applicator, syringe) that does not work as designed. A seal problem can let contamination in after the product leaves the factory, and a failed child-resistant cap puts children at risk of accidental exposure.

Class II · Moderate risk

Vitamin D3

cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.

Ongoing Packaging defect Safecor Health, LLC NDC 48433-104-01 D-0056-2025
Class II · Moderate risk

Xelstrym (dextroamphetamine)

Defective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive).

Ongoing Packaging defect Noven Pharmaceuticals Inc NDC 68968-0215-3 D-0055-2025
Class II · Moderate risk

Timolol Maleate Ophthalmic Solution USP

Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Ongoing Packaging defect FDC Limited NDC 64980-514-05 D-0035-2025
Class III · Low risk

Ciclopirox Gel 0.77%

Defective Container: Firm received complaints of broken tube at the seal.

Ongoing Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-0455-35 D-0002-2025
Class III · Low risk

Varithena (polidocanol injectable foam)

Defective Delivery System: incorrect silicone oil-free NormJect 10 mL Luer Lock Solo syringes packaged in the pack, instead of the required silicone oil-free NormJect 10 mL Luer Solo syringes (luer slip connection).

Terminated Packaging defect Biocompatibles UK, Ltd. D-0113-2025
Class II · Moderate risk

Timolol Maleate Ophthalmic Solution USP

Defective Container: patients are unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

Ongoing Packaging defect FDC Limited NDC 64980-514-05 D-0642-2024
Class II · Moderate risk

Ciprofloxacin ophthalmic solution USP

Defective container: unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

Ongoing Packaging defect FDC Limited NDC 69315-308-10 D-0623-2024
Class III · Low risk

Peg-3350

Defective container: potential for non-sealed pouches which can lead to product leakage.

Terminated Packaging defect Novel Laboratories, Inc. d.b.a Lupin Somerset NDC 0093-3560-26 D-0628-2024
Class II · Moderate risk

Timolol Maleate Ophthalmic Solution

Defective Container: yellow-colored spike from cap lodged in the nozzle. Firm received several complaints from customers.

Terminated Packaging defect FDC Limited NDC 64980-514-05 D-0488-2024
Class III · Low risk

Clindamycin Phosphate

Defective Container: Out of specification for weight due to a slow leakage at the 12-month stability timepoint.

Ongoing Packaging defect Contract Pharmaceuticals Limited Canada NDC 10135-0691-61 D-0364-2024
Class II · Moderate risk

Lansoprazole Delayed-Release Capsules USP

CGMP Deviations: Inadequate induction sealing on bottles, capsules were observed with bubbles on band seal, capsules with holes and spheres sticking to capsules. Also coding details were missing on one bottle.

Terminated Packaging defect NATCO Pharma Limited NDC 16571-742-41 D-0318-2024
Class I · High risk

Albuterol Sulfate Inhalation Aerosol

Defective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bottom seat (gasket).

Terminated Packaging defect Cipla USA, Inc. NDC 69097-142-60 D-0938-2023